What Ruxandra Teslo thinks about innovation
Geneticist by training and writer on science, medicine and policy. She holds a PhD in genomics, writes at Ruxandra's Substack and for Works in Progress, and co-founded Clinical Trial Abundance, a project arguing that the binding constraint on new medicines is how trials are run rather than how drugs are designed.
Ruxandra Teslo did not write this page.
We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.
Filter innovation · Newest first
Only Ruxandra Teslo on innovation. See everyone on innovation
2 dated positions, 2026, in their own words. Our reading of what Ruxandra Teslo has said — not written or endorsed by them.
-
Their wordsTake Eroom’s Law: the number of new drugs approved per dollar of R&D has fallen for decades, even as our scientific tools have grown vastly more powerful, the exact opposite of what the existence of more raw capability would predict.
↗Intelligence is not the main bottleneckwritingruxandrabio.com 2nd of 6 in this piece
-
Their wordsA capability existing is not the same as a capability being absorbed into institutions, and, perhaps most important of all, translated into outcomes people care about.
↗Intelligence is not the main bottleneckwritingruxandrabio.com 6th of 6 in this piece